Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights.
Adverse events
Bnt162b2
Covid-19
Herpes virus
Herpes zoster rash
Mrna-1273
Journal
European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
19
04
2022
revised:
18
07
2022
accepted:
29
07
2022
pubmed:
6
8
2022
medline:
4
10
2022
entrez:
5
8
2022
Statut:
ppublish
Résumé
Varicella zoster virus (VZV) reactivation has been reported following vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the real extent remains unknown. We conducted a systematic review to summarize evidence of VZV reactivation or infection following SARS-CoV-2 vaccination. Episodes after coronavirus disease-2019 (COVID-19) were also identified. Related articles were identified in PubMed and EMBASE databases till December 31, 2021 using the terms "varicella zoster" and "COVID-19″. PROSPERO Register Number: CRD42021289399. The search revealed 314 articles, of which 55 met the inclusion criteria. VZV manifestations were documented in 179 (82.1%) subjects following SARS-CoV-2 vaccination and in 39 (17.9%) patients with COVID-19. Among the vaccinated, median (IQR) age was 56.5 (42-70) years, and 56.8% were female. Twenty-one (16.8%) were immunosuppressed. The median (IQR) latency time after vaccination was 6 (3-10) days, and 84.4% received mRNA vaccines. VZV reactivation occurred following a first dose (68.2%), a second dose (12.8%) or a booster (0.6%). The most important VZV manifestation was dermatome herpes zoster rash, which accounted for 86.4% of events in vaccinated subjects. Twenty patients (11.3%) presented serious VZV events after vaccination, with Herpes Zoster ophthalmicus (5.6%) and post-herpetic neuralgia (3.4%) predominating. No VZV pneumonia or deaths were recorded. Antiviral prescriptions were made in 96.2% of vaccinated subjects. No significant differences between vaccinated and infected subjects were found. This study indicates that the occurrence of VZV reactivation is clinically relevant. However, our findings suggest that COVID-19 vaccination is safe, and remains strongly recommended.
Identifiants
pubmed: 35931613
pii: S0953-6205(22)00270-9
doi: 10.1016/j.ejim.2022.07.022
pmc: PMC9340059
pii:
doi:
Substances chimiques
Antiviral Agents
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-79Informations de copyright
Copyright © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Références
Ann Dermatol Venereol. 2022 Mar;149(1):58-60
pubmed: 34711399
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e85-e86
pubmed: 34606142
QJM. 2021 Nov 5;114(7):531-532
pubmed: 34293165
Dermatol Ther (Heidelb). 2021 Aug;11(4):1119-1126
pubmed: 33999370
Neurol Clin Pract. 2021 Apr;11(2):e219-e221
pubmed: 33842100
Lancet Reg Health West Pac. 2022 Apr;21:100393
pubmed: 35128500
Cureus. 2021 Oct 1;13(10):e18418
pubmed: 34733594
J Pain Res. 2020 Sep 22;13:2361-2365
pubmed: 33061551
J Cosmet Dermatol. 2021 Jun;20(6):1566-1567
pubmed: 33638924
JAAD Case Rep. 2021 Nov;17:126-129
pubmed: 34568532
Viruses. 2018 Jun 28;10(7):
pubmed: 29958408
Eur J Ophthalmol. 2021 Sep 18;:11206721211046485
pubmed: 34541931
Infection. 2022 Apr;50(2):289-293
pubmed: 34807403
Open Forum Infect Dis. 2016 Oct 19;3(4):ofw184
pubmed: 27807590
Clin Exp Vaccine Res. 2021 May;10(2):198-201
pubmed: 34222134
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e620-e622
pubmed: 34058038
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e750-e752
pubmed: 34310754
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):435-442
pubmed: 33840920
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e306-e307
pubmed: 32330340
Open Forum Infect Dis. 2020 Jan 09;7(1):ofaa005
pubmed: 32010734
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213
pubmed: 32215952
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e745-e747
pubmed: 34310759
Cureus. 2021 Jan 1;13(1):e12423
pubmed: 33542871
Pediatr Blood Cancer. 2021 Oct;68(10):e29191
pubmed: 34180130
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e846-e847
pubmed: 34363257
Dermatol Ther. 2020 Nov;33(6):e13930
pubmed: 32602610
Int J Dermatol. 2020 Aug;59(8):1028-1029
pubmed: 32530063
Proc R Soc Med. 1965 May;58:295-300
pubmed: 14283879
Semin Respir Crit Care Med. 2021 Dec;42(6):759-770
pubmed: 34918319
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e6-e9
pubmed: 34487581
JAAD Case Rep. 2021 Sep;15:60-61
pubmed: 34316506
J Cosmet Dermatol. 2021 Nov;20(11):3389-3390
pubmed: 34077622
J Drugs Dermatol. 2021 Aug 1;20(8):898-900
pubmed: 34397201
Infect Dis Clin Pract (Baltim Md). 2021 Mar;29(2):e109-e110
pubmed: 34191904
J Ophthalmic Inflamm Infect. 2021 Sep 16;11(1):28
pubmed: 34529153
J Cosmet Dermatol. 2021 Nov;20(11):3384-3386
pubmed: 34510694
Clin Microbiol Infect. 2022 Jan;28(1):130-134
pubmed: 34592420
Int J Dermatol. 2020 Dec;59(12):1545-1546
pubmed: 33040343
Int J Infect Dis. 2021 Oct;111:169-171
pubmed: 34428545
Eur J Neurol. 2020 Sep;27(9):1748-1750
pubmed: 32449248
Nat Med. 2021 Jan;27(1):28-33
pubmed: 33442016
Viruses. 2018 Nov 02;10(11):
pubmed: 30400213
Can J Microbiol. 2022 May;68(5):303-314
pubmed: 35167378
Environ Sci Pollut Res Int. 2021 Dec;28(46):65769-65775
pubmed: 34322810
JAAD Case Rep. 2020 Jul;6(7):656-657
pubmed: 32572380
Dermatol Ther. 2020 Jul;33(4):e13666
pubmed: 32447801
Nat Rev Microbiol. 2014 Mar;12(3):197-210
pubmed: 24509782
J Am Acad Dermatol. 2020 Sep;83(3):e257-e259
pubmed: 32585280
Inflamm Res. 2021 Sep;70(9):935-937
pubmed: 34390376
Int J Infect Dis. 2021 Dec;113:55-57
pubmed: 34587536
J Neurol. 2022 Apr;269(4):1751-1757
pubmed: 34724572
J Dermatolog Treat. 2022 Mar;33(2):1123-1125
pubmed: 32543328
Epidemiol Infect. 2021 Jun 16;149:e145
pubmed: 34130765
Cureus. 2020 Jul 4;12(7):e8998
pubmed: 32670724
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
BMJ Evid Based Med. 2018 Apr;23(2):60-63
pubmed: 29420178
J Med Virol. 2021 Sep;93(9):5231-5232
pubmed: 33913545
Infez Med. 2020 Sep 1;28(3):351-356
pubmed: 32920570
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Adv Wound Care (New Rochelle). 2021 Feb;10(2):51-80
pubmed: 33035150
Br J Dermatol. 2022 Jan;186(1):142-152
pubmed: 34254291
Cutis. 2020 Dec;106(6):318-320
pubmed: 33471879
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI90-SI95
pubmed: 33848321
Bioinform Biol Insights. 2021 Jun 22;15:11779322211025876
pubmed: 34220199
Respir Care. 2009 Oct;54(10):1372-8
pubmed: 19796418
Cornea. 2022 Feb 1;41(2):254-256
pubmed: 34690265
JAAD Case Rep. 2021 Jun;12:58-59
pubmed: 33937467
Expert Rev Vaccines. 2022 May;21(5):675-684
pubmed: 35191364
J Cosmet Dermatol. 2021 Nov;20(11):3376-3377
pubmed: 34559453
Vaccines (Basel). 2021 Jun 01;9(6):
pubmed: 34205861
Cureus. 2021 Jul 29;13(7):e16725
pubmed: 34471577
Cureus. 2021 Jul 8;13(7):e16274
pubmed: 34377609
Eur J Dermatol. 2020 Dec 1;30(6):754-756
pubmed: 33262097
J Cosmet Dermatol. 2021 Jul;20(7):1960-1964
pubmed: 33991162
Br J Dermatol. 2020 Dec;183(6):1145-1147
pubmed: 32790074
BMC Public Health. 2013 Feb 19;13:154
pubmed: 23421987